- PackSize
- 50ug/100ug
- Target
- Envelope glycoprotein B
- Reactivity
- Human cytomegalovirus (HCMV/HHV-5)
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Human
- Isotype
- IgG1, kappa
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- Envelope glycoprotein B, gB, UL55
- Species
- --
- Gene ID-1
- P06473
- Uniprot
- --
- Background
- Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --